Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.44 |
| ▸ | KIT | P10721 | 2/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.42 |
| ▸ | CKS1B | P61024 | 1/20 | 0.42 |
| ▸ | SKP1 | P63208 | 1/20 | 0.42 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.42 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 8/20 | 0.40 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.40 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3616822 | 0.96 | NR1H2 (0.47) | NR1H2NR1H3KITGPR119TBK1 | |
| SCHEMBL14283157 | 0.87 | KIT (0.47) | KITCKS1BSKP1SKP2TBK1 | |
| SCHEMBL3604476 | 0.83 | MAPKAPK2 (0.39) | NR1H2NR1H3KITGPR119CKS1B | |
| SCHEMBL3604480 | 0.83 | MAPKAPK2 (0.39) | NR1H2NR1H3KITGPR119CKS1B | |
| SCHEMBL14283324 | 0.83 | KIT (0.49) | KITGPR119CKS1BSKP1SKP2 | |
| SCHEMBL3616068 | 0.83 | RET (0.51) | RET | |
| SCHEMBL3617867 | 0.81 | RET (0.45) | CKS1BSKP1SKP2RET | |
| SCHEMBL3618285 | 0.81 | ROCK2 (0.40) | TBK1KMT2A | |
| SCHEMBL3611277 | 0.81 | NR1H2 (0.45) | NR1H2NR1H3KITGPR119TBK1 | |
| SCHEMBL20597942 | 0.80 | NR1H2 (0.47) | NR1H2NR1H3KITGPR119RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105664-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-04-29 | — | — | US | disclosed |
| US-20100105664-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105664-A1 | ORGANIC COMPOUNDS | SLCO1B3, SLCO1B1, SLC10A6 | NR1H2 387/4885NR1H3 238/4885KIT 871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.